AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat
November 5, 2019 7:22 AM ESTMizuho Securities analyst Difei Yang reiterated a Buy rating and $30.00 price target on Evolus (NASDAQ: EOLS) following the company's 3Q earnings report. Both revenue and EPS came in above consensus estimates, driven by strong sales from Jeuveau in the... More
Evolus (EOLS) Tops Q3 EPS by 15c, Revenues Beat
November 4, 2019 7:09 AM ESTEvolus (NASDAQ: EOLS) reported Q3 EPS of ($0.98), $0.15 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $4.05 million.
This was an exceptional quarter for the company on many fronts, in the U.S. and internationally,... More
